Watanabe-Fukunaga, Brannan, Copeland et al.: "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis." in: Nature, Vol. 356, Issue 6367, pp. 314-7, 1992 (PubMed).
Kobayashi, Hamamoto, Yamamoto et al.: "Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 87, Issue 24, pp. 9620-4, 1991 (PubMed).
Yonehara, Ishii, Yonehara: "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor." in: The Journal of experimental medicine, Vol. 169, Issue 5, pp. 1747-56, 1989 (PubMed).
Boirivant, Pica, DeMaria et al.: "Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis." in: The Journal of clinical investigation, Vol. 98, Issue 11, pp. 2616-22, 1997 (PubMed).
Ando, Hiroishi, Kaneko et al.: "Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 158, Issue 11, pp. 5283-91, 1997 (PubMed).
Dai, Price, Brunner et al.: "Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis." in: Blood, Vol. 91, Issue 4, pp. 1235-42, 1998 (PubMed).
Kuwano, Miyazaki, Hagimoto et al.: "The involvement of Fas-Fas ligand pathway in fibrosing lung diseases." in: American journal of respiratory cell and molecular biology, Vol. 20, Issue 1, pp. 53-60, 1999 (PubMed).
Hiromatsu, Hoshino, Yagita et al.: "Functional Fas ligand expression in thyrocytes from patients with Graves' disease." in: The Journal of clinical endocrinology and metabolism, Vol. 84, Issue 8, pp. 2896-902, 1999 (PubMed).
Sata, Suhara, Walsh: "Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy." in: Arteriosclerosis, thrombosis, and vascular biology, Vol. 20, Issue 2, pp. 309-16, 2000 (PubMed).
Shinohara, Yagita, Ikawa et al.: "Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation." in: Cancer research, Vol. 60, Issue 6, pp. 1766-72, 2000 (PubMed).
Suhara, Kim, Kirshenbaum et al.: "Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation." in: Molecular and cellular biology, Vol. 22, Issue 2, pp. 680-91, 2001 (PubMed).
Suhara, Fukuo, Yasuda et al.: "Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways." in: Hypertension, Vol. 43, Issue 6, pp. 1208-13, 2004 (PubMed).
Mezosi, Wang, Utsugi et al.: "Induction and regulation of Fas-mediated apoptosis in human thyroid epithelial cells." in: Molecular endocrinology (Baltimore, Md.), Vol. 19, Issue 3, pp. 804-11, 2005 (PubMed).
Hauptschein, Sloan, Torella et al.: "Functional proteomic screen identifies a modulating role for CD44 in death receptor-mediated apoptosis." in: Cancer research, Vol. 65, Issue 5, pp. 1887-96, 2005 (PubMed).
Vega, Jazirehi, Huerta-Yepez et al.: "Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 4, pp. 2174-83, 2005 (PubMed).